MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith purchased 25,000 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $1.87 per share, with a total value of $46,750.00. Following the completion of the purchase, the director now owns 1,130,060 shares of the company's stock, valued at $2,113,212.20. The trade was a 2.26 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
MAIA traded down $0.01 during trading on Friday, hitting $2.00. The stock had a trading volume of 70,324 shares, compared to its average volume of 273,036. MAIA Biotechnology, Inc. has a twelve month low of $0.85 and a twelve month high of $5.99.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.21. Equities analysts expect that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Ground Swell Capital LLC acquired a new stake in MAIA Biotechnology in the second quarter worth $56,000. Geode Capital Management LLC grew its holdings in shares of MAIA Biotechnology by 22.9% during the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company's stock valued at $541,000 after acquiring an additional 35,821 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of MAIA Biotechnology during the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 5.65% of the company's stock.
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.